A-Alpha Bio Raises $22.4M in Series A2 Funding

A-Alpha Bio

A-Alpha Bio, a Seattle, WA-based synthetic biology and machine learning (ML) company that measures and engineers protein-protein interactions, raised $22.4M in Series A2 funding.

The round, which brought the total amount to total funding to $51M, was led by previous investor Perceptive Xontogeny Ventures, with participation from Madrona and other existing investors. Breakout Ventures joined the round as a new investor, and Lindy Fishburne, Managing Partner at Breakout Ventures, will join the board as an observer.

The company intends to use the funds for further development of its AlphaSeq and AlphaBind platforms and accelerate their oncology-focused internal pipeline.

Led by CEO David Younger, A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions. Its AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously. Protein binding data is incorporated into the company’s AlphaBind platform to train machine learning models that predict binding from sequence. A-Alpha Bio uses both platforms to discover and optimize high-impact therapeutics for their own pipeline and in partnership with industry leaders.

In pursuit of their mission to accelerate therapeutic discovery to improve human health, the company recently announced collaborations with Bristol Myers Squibb, Lawrence Livermore National Laboratory, and Gilead Sciences to discover molecular glue targets for protein degradation, accelerate antibody discovery and development for emerging biothreats, and advance next-generation HIV therapeutic options, respectively.